Immunomedics Stock Price, News & Analysis (NASDAQ:IMMU)

$11.39 -0.19 (-1.64 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$11.58
Today's Range$11.15 - $11.72
52-Week Range$3.01 - $14.48
Volume2.46 million shs
Average Volume3.09 million shs
Market Capitalization$1.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.55

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web: www.immunomedics.com
Debt:
  • Debt-to-Equity Ratio: -0.29%
  • Current Ratio: 0.74%
  • Quick Ratio: 0.74%
Sales & Book Value:
  • Annual Sales: $3.09 million
  • Price / Sales: 560.36
  • Book Value: ($0.54) per share
  • Price / Book: -21.09
Profitability:
  • Trailing EPS: ($2.24)
  • Net Income: $-153,200,000.00
  • Net Margins: -8,412.93%
  • Return on Assets: -83.13%
Misc:
  • Employees: 138
  • Outstanding Shares: 152,020,000
 

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings data on Thursday, February, 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.03. The biopharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $0.70 million. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 analysts have issued 12-month price objectives for Immunomedics' stock. Their predictions range from $15.00 to $16.00. On average, they anticipate Immunomedics' share price to reach $15.50 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 23,120,634 shares, a drop of 14.6% from the October 13th total of 27,080,391 shares. Based on an average trading volume of 2,189,840 shares, the short-interest ratio is currently 10.6 days. Approximately 16.9% of the shares of the company are sold short.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Behzad Aghazadeh Ph.D., Independent Chairman of the Board (Age 46)
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance (Age 59)
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director (Age 79)
  • Brendan Delaney, Chief Commercial Officer
  • Cynthia L. Sullivan, Director (Age 61)
  • Scott A. Canute, Independent Director (Age 57)
  • Peter Barton Hutt, Independent Director (Age 82)
  • Khalid Islam Ph.D., Independent Director (Age 61)
  • Brian A. Markison, Lead Independent Director (Age 58)

Who owns Immunomedics stock?

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (6.58%), NEA Management Company LLC (1.83%), Jennison Associates LLC (1.20%), Pictet Asset Management Ltd. (0.99%), Bank of New York Mellon Corp (0.45%) and Iguana Healthcare Management LLC (0.33%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, EAM Investors LLC, Sphera Funds Management LTD., Wells Fargo & Company MN, Allianz Asset Management GmbH, Candriam Luxembourg S.C.A., Public Employees Retirement Association of Colorado and California State Teachers Retirement System. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Pictet Asset Management Ltd., Jennison Associates LLC, Nicholas Investment Partners LP, Schwab Charles Investment Management Inc., Lyon Street Capital LLC, Chicago Equity Partners LLC and Bank of New York Mellon Corp. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $11.39.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $1.73 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 the American Rd, MORRIS PLAINS, NJ 07950-2460, United States. The biopharmaceutical company can be reached via phone at +1-973-6058200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Immunomedics (NASDAQ:IMMU)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.50 (36.08% upside)

Consensus Price Target History for Immunomedics (NASDAQ:IMMU)

Price Target History for Immunomedics (NASDAQ:IMMU)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Jefferies Group LLCBoost Price TargetBuy$14.00 -> $16.00N/AView Rating Details
7/24/2017Cowen and CompanyReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CompanyUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Immunomedics (NASDAQ:IMMU)

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Earnings History by Quarter for Immunomedics (NASDAQ IMMU)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ IMMU)

Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 62.61%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Insider Trades by Quarter for Immunomedics (NASDAQ IMMU)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2017Brian A MarkisonDirectorSell8,390$11.89$99,757.10View SEC Filing  
11/15/2017Behzad AghazadehInsiderBuy1,325,000$10.47$13,872,750.00View SEC Filing  
11/14/2017Venbio Select Advisor LlcDirectorBuy1,150,000$10.39$11,948,500.00View SEC Filing  
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immunomedics (NASDAQ IMMU)

Source:
DateHeadline
Immunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 SharesImmunomedics, Inc. (IMMU) Director Brian A. Markison Sells 8,390 Shares
www.americanbankingnews.com - November 21 at 9:10 PM
Immunomedics (IMMU) Jumps: Stock Rises 5.4%Immunomedics (IMMU) Jumps: Stock Rises 5.4%
finance.yahoo.com - November 17 at 6:32 AM
Options Traders Expect Huge Moves in Immunomedics (IMMU) StockOptions Traders Expect Huge Moves in Immunomedics (IMMU) Stock
finance.yahoo.com - November 17 at 6:32 AM
Venbio Select Advisor Llc Acquires 1,150,000 Shares of Immunomedics, Inc. (IMMU) StockVenbio Select Advisor Llc Acquires 1,150,000 Shares of Immunomedics, Inc. (IMMU) Stock
www.americanbankingnews.com - November 16 at 4:22 PM
Insider Buying: Immunomedics, Inc. (IMMU) Insider Purchases 1,325,000 Shares of StockInsider Buying: Immunomedics, Inc. (IMMU) Insider Purchases 1,325,000 Shares of Stock
www.americanbankingnews.com - November 15 at 7:31 PM
Wells defends Immunomedics, 19% selloff a "buying opportunity" - Seeking AlphaWells defends Immunomedics, 19% selloff a "buying opportunity" - Seeking Alpha
seekingalpha.com - November 15 at 2:55 AM
Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium - GlobeNewswire (press release)Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium - GlobeNewswire (press release)
globenewswire.com - November 15 at 2:55 AM
Immunomedics Emerges With New Leadership - Seeking AlphaImmunomedics Emerges With New Leadership - Seeking Alpha
seekingalpha.com - November 15 at 2:55 AM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017
finance.yahoo.com - November 13 at 7:54 PM
Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer SymposiumImmunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - November 13 at 7:54 PM
44 Biggest Movers From Friday - Benzinga44 Biggest Movers From Friday - Benzinga
www.benzinga.com - November 13 at 6:21 AM
Immunomedics, Inc. (IMMU) Short Interest UpdateImmunomedics, Inc. (IMMU) Short Interest Update
www.americanbankingnews.com - November 12 at 1:32 AM
Immunomedics (IMMU) Appoints Michael Pehl as President and CEOImmunomedics (IMMU) Appoints Michael Pehl as President and CEO
www.streetinsider.com - November 11 at 12:11 PM
Investor Network: Immunomedics, Inc. to Host Earnings CallInvestor Network: Immunomedics, Inc. to Host Earnings Call
www.finanznachrichten.de - November 11 at 12:11 PM
BRIEF-Immunomedics appoints Michael Pehl president and CEOBRIEF-Immunomedics appoints Michael Pehl president and CEO
www.reuters.com - November 11 at 12:11 PM
Immunomedics, Inc. to Host Earnings CallImmunomedics, Inc. to Host Earnings Call
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative GrowthImmunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate UpdateImmunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics reports 1Q lossImmunomedics reports 1Q loss
finance.yahoo.com - November 11 at 12:10 PM
Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMTEdited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT
finance.yahoo.com - November 11 at 12:10 PM
Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017
finance.yahoo.com - November 3 at 9:46 AM
Immunomedics, Inc. (IMMU) Given Average Rating of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 2 at 3:30 PM
Comparing Immunomedics (IMMU) and Oramed Pharmaceuticals (ORMP)Comparing Immunomedics (IMMU) and Oramed Pharmaceuticals (ORMP)
www.americanbankingnews.com - November 1 at 1:22 AM
ETFs with exposure to Immunomedics, Inc. : October 31, 2017ETFs with exposure to Immunomedics, Inc. : October 31, 2017
finance.yahoo.com - October 31 at 10:23 PM
Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : October 31, 2017Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : October 31, 2017
finance.yahoo.com - October 31 at 10:23 PM
Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : October 30, 2017
finance.yahoo.com - October 30 at 10:06 PM
Interesting IMMU Put And Call Options For December 15thInteresting IMMU Put And Call Options For December 15th
www.thestreet.com - October 25 at 6:27 AM
Technical Insights on Biotech Stocks -- Conatus Pharma ... - PR Newswire (press release)Technical Insights on Biotech Stocks -- Conatus Pharma ... - PR Newswire (press release)
www.prnewswire.com - October 18 at 1:14 AM
Immunomedics, Inc. (IMMU) Sees Large Decline in Short InterestImmunomedics, Inc. (IMMU) Sees Large Decline in Short Interest
www.americanbankingnews.com - October 13 at 1:32 AM
Immunomedics, Inc. (IMMU) PT Raised to $16.00 at Jefferies Group LLCImmunomedics, Inc. (IMMU) PT Raised to $16.00 at Jefferies Group LLC
www.americanbankingnews.com - October 9 at 8:58 PM
Financial Comparison: Intrexon Corporation (XON) & Immunomedics (IMMU)Financial Comparison: Intrexon Corporation (XON) & Immunomedics (IMMU)
www.americanbankingnews.com - October 8 at 4:24 PM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 8 at 12:50 PM
Immunomedics Reaches Analyst Target PriceImmunomedics Reaches Analyst Target Price
www.nasdaq.com - October 5 at 9:50 PM
Immunomedics, Inc. (IMMU) Stock Rating Upgraded by Zacks Investment ResearchImmunomedics, Inc. (IMMU) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 4 at 11:10 PM
ETFs with exposure to Immunomedics, Inc. : October 3, 2017ETFs with exposure to Immunomedics, Inc. : October 3, 2017
finance.yahoo.com - October 4 at 5:22 PM
OvaScience (OVAS) & Immunomedics (IMMU) Head to Head ComparisonOvaScience (OVAS) & Immunomedics (IMMU) Head to Head Comparison
www.americanbankingnews.com - October 1 at 8:24 AM
Head to Head Contrast: Immunomedics (IMMU) and Protagonist Therapeutics (PTGX)Head to Head Contrast: Immunomedics (IMMU) and Protagonist Therapeutics (PTGX)
www.americanbankingnews.com - September 25 at 12:18 PM
Immunomedics, Inc. (IMMU) Given New $14.00 Price Target at Jefferies Group LLCImmunomedics, Inc. (IMMU) Given New $14.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - September 24 at 1:00 PM
Form 8-K IMMUNOMEDICS INC For: Sep 19 - StreetInsider.comForm 8-K IMMUNOMEDICS INC For: Sep 19 - StreetInsider.com
www.streetinsider.com - September 22 at 7:02 PM
Jefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU)Jefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU)
www.americanbankingnews.com - September 21 at 11:20 AM
Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common StockImmunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock
finance.yahoo.com - September 16 at 1:40 AM
Immunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowImmunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 6:28 AM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by AnalystsImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 13 at 2:53 PM
BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (iBRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i
www.reuters.com - September 12 at 1:39 AM
Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial CancerImmunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
finance.yahoo.com - September 12 at 1:39 AM
Immunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - StreetInsider.comImmunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - StreetInsider.com
www.streetinsider.com - September 11 at 8:36 PM
Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - NasdaqAre Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - Nasdaq
www.nasdaq.com - September 11 at 8:36 PM
Immunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 SharesImmunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 Shares
www.americanbankingnews.com - September 5 at 10:26 PM
IMMU Crosses Above Average Analyst Target - NasdaqIMMU Crosses Above Average Analyst Target - Nasdaq
www.nasdaq.com - September 1 at 8:13 PM
Immunomedics to Participate in Upcoming Investor ConferencesImmunomedics to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 31 at 6:10 AM

Social Media

Financials

Chart

Immunomedics (NASDAQ IMMU) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.